Ullman Quoted in Article on FDA’s Enforcement Discretion for CBD

April 26, 2022 | Compliance Investigations & White Collar | Cannabis

Marc Ullman was quoted in the Natural Products Insider article, “FDA written enforcement discretion on CBD unlikely.”

The article discusses how the FDA is unlikely to issue a formal policy of enforcement discretion for CBD-containing products marketed as dietary supplements.

Ullman doesn’t believe the agency would issue a CBD enforcement discretion policy similar to NAC. “FDA has said, ‘We have safety concerns,’ and if they have safety concerns, how can they say we’re not going to take enforcement action?” asked Ullman.

Read the full article here.

Share this article:

Related News

Get legal updates and news delivered to your inbox